BioTime (NYSEMKT: BTX), a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies.
BTX’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis.
BTX also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products.
Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia.
BioTime, Inc. was founded in 1990 and is based in Alameda, California.
March 20, 2019
RegMed Investors’ (RMi) closing bell: even a FDA approval (SAGE) for postpartum depression and a Pfizer (PFE) option to purchase a gene therapy company (Vivet Therapeutics) did not move the risk indicator
March 19, 2019
RegMed Investors’ (RMi) pre-open: feeling a hiccup coming
March 13, 2019
RegMed Investors’ (RMi) closing bell: the sector perks-up
45 companies, 1 interpreter!
Insight, foresight and recommendation
BioTime, Inc. (BTX) -- open 1/1/18 at $2.29, rolled to $3.05 by 2/1 but, has been slipping to $2.60 on 2/16. Needs news and differentiation of the story and the definition of their multiple markets addressed ... also rolls with news yet a complacent stock ...hold
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at email@example.com.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors